The Nucleus 22-channel cochlear implant system.
Cochlear implants have become the treatment of choice for profoundly deaf adults and children who obtain little or no benefit from conventional amplification. Sounds are translated into small electric currents that stimulate the auditory nerves in the cochlea and generate hearing sensations. The Nucleus cochlear implant is the result of more than 20 yr of research and development, first at the University of Melbourne, Australia and later by Cochlear Proprietary Limited (Sydney, Australia) in collaboration with the University of Melbourne. Today, the cochlear Mini-22 implant system is approved by the United States Food and Drug Administration (FDA) for use in adults and children, and has been implanted in more than 3000 patients worldwide. Although this chapter describes the cochlear implant system and clinical issues related to its use in children, much of the material has been derived from experience with adults. Furthermore, the Nucleus system is not static. It is being continually improved both in performance and ease of use. The purpose of this chapter is to describe developments leading up to and including the present Nucleus cochlear implant system. Other chapters in this issue present results and procedures relating to pediatric applications of the device.
Patrick
J F
JF
Cochlear Proprietary Limited, New South Wales, Australia.
Clark
G M
GM
D000328:Adult; D000818:Animals; D002648:Child; D003054:Cochlear Implants / Q000266:history; D003638:Deafness / Q000534:rehabilitation; D004582:Electronics, Medical / Q000266:history; D049673:History, 20th Century; D006801:Humans